help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2004-1769
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Germeyer, A.
Right arrow Articles by Nayak, N. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Germeyer, A.
Right arrow Articles by Nayak, N. R.
Related Collections
Right arrow Female Endocrinology
The Journal of Clinical Endocrinology & Metabolism Vol. 90, No. 3 1783-1790
Copyright © 2005 by The Endocrine Society

Cellular Expression and Hormonal Regulation of Neuropilin-1 and -2 Messenger Ribonucleic Acid in the Human and Rhesus Macaque Endometrium

Ariane Germeyer, Amy E. Hamilton, Lisa S. Laughlin, Bill L. Lasley, Robert M. Brenner, Linda C. Giudice and Nihar R. Nayak

Department of Gynecology and Obstetrics (A.G., A.E.H., L.C.G., N.R.N.), Stanford University, Stanford, California 94305; California National Primate Research Center (L.S.L., B.L.L.), University of California-Davis, Davis, California 95616; and Oregon National Primate Research Center (R.M.B.), Beaverton, Oregon 97006

Address all correspondence and requests for reprints to: Nihar R. Nayak, Ph.D., Department of Gynecology and Obstetrics, Stanford University School of Medicine, 300 Pasteur Drive, HH-333, Stanford, California 94305-5317. E-mail: nayakn{at}stanford.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Although much is known about the biology of vascular endothelial growth factor (VEGF) and its cognate receptors (VEGFRs), VEGFR1 and VEGFR2, little is known about the roles of the VEGFRs neuropilin (NP)-1 and NP-2 in the primate endometrium. In this study, we investigated the cellular localization and hormonal regulation of NP-1 and NP-2 mRNA by in situ hybridization in the endometrium of ovariectomized, hormonally cycled rhesus macaques and women during the natural menstrual cycle. NP-1 mRNA was highly expressed in vascular endothelium and in stromal cells, but in these cells, NP-1 expression did not change during the menstrual cycle. However, NP-1 mRNA was also expressed in the luminal epithelium (not the glands), and its expression in these cells was elevated during the mid- to late proliferative phase and completely suppressed during the secretory phase. The increase in NP-1 level in the luminal epithelium was estradiol dependent because such expression was not detectable in the absence of estradiol in ovariectomized, hormone-deprived animals. Moreover, NP-1 expression in the luminal epithelium was highly correlated with the degree of proliferation in these cells. A recent study showed that blockade of VEGF action can inhibit luminal epithelial cell proliferation, but there is no evidence of VEGFR1 and VEGFR2 expression in these cells. Therefore, NP-1 may be the relevant VEGFR that mediates proliferation in this epithelium. NP-2 mRNA, unlike NP-1, was expressed only by the endothelium of veins, and in these cells, its expression was hormonally regulated in the converse manner: it was very low during the proliferative phase and high during the secretory phase. The increased permeability and edema observed during the secretory phase in the primate endometrium may be mediated in part by VEGF-NP-2 interaction. In the human endometrium, the pattern of expression and cellular localization of both NP-1 and NP-2 during the menstrual cycle were essentially identical with that seen in the rhesus macaque endometrium. These are the first data to specify the hormonal regulation and cell-specific expression of NP-1 and NP-2 mRNA in the endometrium of both women and nonhuman primates. The findings extend our understanding of VEGF action in the primate endometrium.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
IN WOMEN AND nonhuman primates, the endometrium undergoes dramatic cyclic changes involving growth and remodeling (1, 2). During the proliferative phase, estrogen stimulates angiogenesis and cell proliferation, leading to increased tissue mass. During the following secretory phase, progesterone (P) initiates remodeling of the endometrial tissue and prepares it for implantation. When the corpus luteum regresses and P levels fall, the uppermost endometrial layers are shed (2), and the cycle begins anew. Several local factors are believed to play key roles in mediating these remarkable tissue changes (1, 3, 4).

Different growth factors belonging to the vascular endothelial growth factor (VEGF) family, including VEGF, placental growth factor, VEGF-B, VEGF-C, and VEGF-D, act as modulators and inducers of angiogenesis, vasculogenesis, and vascular permeability in different organs, including the female reproductive tract (5, 6). Human VEGF encompasses five different isoforms of 121, 145, 165, 189, and 206 amino acids resulting from alternative splicing from a single gene containing eight exons (6). All VEGF splice variants can bind to their receptors (VEGFRs), VEGFR-1 and VEGFR-2, which transmit VEGF actions through their intrinsic tyrosine kinase activity (7). Numerous studies show cyclic changes and hormonal regulation of VEGF in both human and nonhuman primate endometrium during the menstrual cycle and suggest a role of VEGF in endometrial angiogenesis (5). VEGF165 and VEGF121 are the most abundant isoforms expressed in the human endometrium (8, 9), and a recent study (10) shows transient up-regulation of VEGF189 during the secretory phase.

Because VEGFR-1 and VEGFR-2 are typically expressed in endothelial cells, VEGF is considered as an endothelial cell-specific growth factor. However, several reports show VEGF interactions with nonendothelial cells. We previously suggested a link between VEGF-KDR and the menstrual induction cascade based on our observation that VEGFR-2, normally expressed in the vascular endothelium throughout the menstrual cycle, was expressed in the stromal cells of the upper endometrial zones during the premenstrual phase in both human and macaque endometrium (11). VEGF is known to stimulate migration of monocytes and osteoblasts (12, 13, 14), and a recent study shows that blockade of VEGF action can inhibit estradiol (E2)-dependent luminal epithelial cell proliferation in the mouse endometrium (15). However, these cells do not express VEGFR-1 or VEGFR-2. Cell surface receptor cross-linking studies first suggested the existence of additional VEGFRs that are neither VEGFR-1 nor VEGFR-2. Soker et al. (16) identified these VEGFRs as neuropilins (NPs)-1 and -2, originally described as receptors for the semaphorin family of proteins associated with axonal guidance in the developing nervous system (17). Other members of the VEGF family are also ligands for NPs; placental growth factor binds to both NP-1 and NP-2 (18, 19), and VEGF-B binds to NP-1 (20).

NPs are transmembrane glycoproteins of approximately 140 kDa with a short cytoplasmic domain and an extracellular portion, containing three different structural domains. NP-1 is 47% homologous to NP-2 and has higher affinity for VEGF than NP-2 (16). Interestingly, these receptors act as VEGF isoform-specific receptors in both endothelial and nonendothelial cells, and NP-1 enhances the binding of VEGF165 to VEGFR-2 and facilitates VEGF165-mediated chemotaxis (16, 21). VEGF165 can bind to both NP-1 and NP-2, whereas VEGF145 binds to only NP-2 (18, 22). Gene targeting studies implicate NPs as important modulators of VEGF function in vivo. Overexpression of NP-1 results in excess capillary formation and extensive hemorrhage (23), and conditional overexpression of NP-1 in prostate carcinoma causes increased vascular proliferation and vascular density along with suppression of apoptosis (24). NP-1 or NP-2 single knockouts are embryonically lethal [embryonic d (E) 10–10.5] due to neuronal and cardiovascular defects. However, the double NP-1/NP-2 knockout mice die very early (E8.5) due to more severe abnormal vascular phenotype than the single knockouts (25).

Two recent reports demonstrate expression of NPs in both endothelial and nonendothelial cells in the mouse (26) and rat (27) endometrium and suggest a role of VEGF-NP in induction of the vascular permeability and angiogenesis in mouse uterus (26). Despite the dramatic vascular changes that occur in the primate endometrium during each menstrual cycle, the mechanisms of VEGF action in this organ remain unknown. The aim of this study was to examine the temporal and spatial expression of NP-1 and NP-2 in the rhesus macaque endometrium during hormonally controlled menstrual cycles and in the human endometrium during natural menstrual cycles. In rhesus macaques the menstrual cycle is essentially identical with the human cycle (28), and sequential hormonal treatments can be used after ovariectomy to mimic the natural endometrial cycle (2).


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals

All animal studies were conducted at the Oregon National Primate Research Center and the California National Primate Research Center, according to the National Institutes of Health guidelines for use of nonhuman primates under the approved protocol by the respective Primate Center Institutional Animal Care and Use Committee. A total of 20 adult female rhesus macaques (Macaca mulatta) were ovariectomized and artificially cycled as described previously (2, 29). All macaques received sc crystalline E2 (Sigma, St. Louis, MO) implants in the form of 3-cm SILASTIC capsules (Dow Corning Corp., Midland, MI) to induce a proliferative-phase endometrium. After 14 d a 6-cm crystalline progesterone (P) SILASTIC implant was placed sc and remained in place for 14 d to induce a secretory-phase endometrium. Menstruation followed removal of the P implant, whereas the E2 implant was kept in place. Endometrium from all animals was collected at five different time points: early proliferative phase, i.e. endometrium harvested after 5–6 d of P withdrawal (E5/6P; n = 4); midproliferative phase, 8–10 d after P withdrawal (E8/10P; n = 4); late-proliferative phase, 14 d after P withdrawal (E14P; n = 3); midsecretory phase, 7–8 d after P treatment (E+7/8P; n = 3); and late-secretory phase, 14 d after P treatment (E+14P; n = 3). In a second set of animals, both E2 and P implants were removed [hormone deprived (HD)] at the end of the cycle to induce menstruation, and the endometria were collected 10–14 d later (HD 10–14; n = 3). Endometrial tissue samples were collected by hysterectomy or during necropsy, and serum E2 and P concentrations were measured by radioactive immunoassay, as described previously (29, 30). Tissue samples within normal ranges of serum E2 and P levels for the rhesus menstrual cycle, as previously reported, were included in this study (11, 31).

Human subjects

Endometrial samples were also obtained from human subjects undergoing hysterectomy for benign indications during the mid- to late-proliferative (n = 4) and mid- to late-secretory phases (n = 5) of the cycle as described previously (32). All samples were obtained from normally cycling women in the age group between 28 and 39 yr, after informed consent under an approved protocol by the Stanford University Committee on the Use of Human Subjects in Medical Research. Full-thickness endometrial blocks (2–3 mm thickness) were embedded in optimal cutting temperature (OCT) compound and frozen in liquid nitrogen, and 10-µm cryosections were used for NP-1 and -2 in situ hybridization (ISH) as described below. The stage of the cycle was based on last menstrual period and histological evaluation by pathologists (32). Women under any treatment including hormonal preparations in the preceding 3 months were excluded from this study.

Immunocytochemistry (ICC)

A double-immunostaining method that detected both Ki-67 and von Willebrand factor (vWF) in the same sections was used to differentiate proliferating endothelial cells from other proliferating cells in the endometrium (31). Tissues embedded in OCT were cryosectioned at 7 µm, fixed in 0.2% picric acid-2% paraformaldehyde in phosphate buffer saline at pH 7.3 for 10 min at room temperature, rinsed twice for 2 min each in 85% ethanol and 1.5% polyvinylpyrollidone (PVP) at 4 C, and washed in PBS followed by 0.37% glycine in PBS and PVP and then in 0.1% gelatin in PBS and PVP at 4 C. The sections were then incubated 45 min in glucose oxidase (1 U/ml) with Na-Azide (1 mM) and glucose (10 mM) in PBS to block endogenous peroxidase activity. After washing and incubation with blocking serum, the sections were incubated with a mouse monoclonal primary antibody for Ki-67 (1:300, BioGenex Laboratories, Inc., San Ramon, CA) overnight at 4 C, followed by blocking and incubation with a biotinylated second antibody at room temperature. Nuclei of Ki-67-positive cells were stained brown using the ABC kit (Vector Laboratories, Inc., Burlingame, CA) following the manufacturer’s instructions. The sections were again incubated with the primary rabbit polyclonal antibody for vWF (1:4000, Dako Corp., Carpinteria, CA) and the secondary antirabbit antibody. The cytoplasm of endothelial cells was stained blue-gray with a peroxidase substrate kit (Vector Laboratories). The slides were lightly counterstained with hematoxylin, and the number of Ki-67-positive and -negative nuclei in each field were counted under a x40 objective of a microscope (Carl Zeiss, New York, NY) (31). At least 10 different fields in each section were evaluated, and the percentage of proliferating luminal epithelial, glandular, stromal, and endothelial cells was calculated.

RT-PCR and cloning of cDNA

NP-1 and NP-2 cDNAs specific to the rhesus macaque were generated by RT-PCR and cloning as described previously (11). Total RNA was isolated using TRIZOL (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. RNA was treated with DNase (Qiagen, Santa Clarita, CA) and purified thereafter, using RNeasy spin columns (Qiagen). Two micrograms of the sample were reverse transcribed with the Omniscript kit (Qiagen) using oligo (dT)16–18 and random hexamers (Invitrogen) in equal amounts according to the manufacturer’s instructions. The product was amplified with respective primer pairs in a standard PCR, and the amplified product was isolated in agarose gel. The NP-1 cDNA was subcloned into pGEM-T (Promega Corp., Madison, WI) and NP-2 into pGEM-T easy (Promega) vector. A clone with the insert was maxiprepped (Qiagen) and sequenced. NP-1 (forward: 3'-ACCCGCACCTCATTCCTACAT-5', reverse: 3'-TGCTGGGCTGTGAAGTGGAA-5') and NP-2 (forward: 5'-TGTACCGGCATGGCAAAAAC-3', reverse 5'-GATGATGACACCTTTCACTG-3') primers were designed based on the homologous human GenBank sequences BC007533.1 (1682–2018 bp) and AF022860 (1121–1509 bp), respectively. The partial cDNA sequence of both NP-1 and NP-2 were 97% homologous to the corresponding human sequences.

In situ hybridization

35S-UTP-labeled (Amersham Biosciences, Piscataway, NJ) sense and antisense riboprobes from NP-1 and NP-2 cDNA templates were prepared with the MAXIscript in vitro transcription kit from Ambion, Inc. (Austin, TX), purified by mini-Quick Spin RNA columns (Roche Diagnostics Corp., Indianapolis, IN) according to the manufacturer’s instructions, and ISH was performed as described previously (11, 31). Frozen sections (10 µm) of endometrium were mounted on SuperFrost Plus slides (Fisher Scientific, Fair Lawn, NJ) and fixed in 4% paraformaldehyde in PBS for 20 min at 4 C. The tissue sections were rinsed in 2x standard saline citrate (SSC), and acetylated with 0.25% acetic anhydride in 0.1 mol/liter triethanolamine (pH 8.0) for 10 min. Slides were then rinsed in 2x SSC, dehydrated through an ascending series of alcohols, and air dried. Appropriate concentration of the labeled probe was empirically determined by serial dilution, and the sections were incubated at 55 C overnight with the hybridization solutions [10 mmol/liter dithiothreitol, 0.3 mol/liter NaCl, 20 mmol/liter Tris (pH 8.0), 5 mmol/liter EDTA, 1x Denhardt’s solution, 10% dextran sulfate, 50% formamide] containing the respective sense and antisense probes. The slides were then washed in 5x SSC with 10 mM dithiothreitol at 50 C for 45–60 min, followed by 50% formamide and 2x SSC containing 10–15 mM dithiothreitol at 65 C for 20–30 min. Then the slides were incubated in solution A [0.5 M NaCl, 10 mM Tris (pH 7.5), and 5 mM EDTA (pH 8.0)] containing 20 µg/ml RNase A at 37 C for 30 min, rinsed in solution A, and incubated in 50% formamide at 65 C for 20–30 min. The sections were then washed in SSC in descending order (2x SSC, 1x, 0.5x, 0.1x), followed by dehydration in alcohol solution containing 300 mM NH4Ac, vacuum dried, coated with NTB-2 autoradiographic emulsion (Eastman Kodak Co., Rochester, NY), stored at 4 C for 2–3 wk, developed in D-19 (Eastman Kodak), lightly counterstained with hematoxylin, dehydrated in an ascending series of alcohol dilutions, cleared with xylene, and then coverslipped with Permount (Fisher Scientific).

Sections hybridized with the sense probe or treated with RNase showed no specific signals. Grain counts were performed as described previously (31). Silver grains over the stroma and luminal epithelium were expressed as the number of grains per cell, and grains over endothelial cells were expressed as the number of grains per unit area of vascular endothelium.

Statistical analysis

Data were analyzed by one-way ANOVA and Fisher’s protected least significant difference test (31). P < 0.05 was considered significant. Correlations between different attributes and coefficients of simple determination (R2) were calculated using the StatView software (SAS Institute, Cary, NC), as described previously (31).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Nonhuman primates

NP-1 mRNA cellular localization. NP-1 mRNA was expressed by three cell types: stromal cells, vascular endothelial cells (arteries and veins), and luminal epithelial cells, but not by glandular epithelial cells (Fig. 1Go). Dark-field microscopy of the in situ preparations showed clearly that in the stroma, the NP-1 mRNA signal was expressed at a moderate level and did not change under different hormonal conditions (Fig. 1Go, C, G, K, and O). Similarly, in the vascular endothelium, NP-1 mRNA expression was not different under different hormonal conditions (Fig. 2Go). However, in the luminal epithelium, the NP-1 mRNA signal was very high in the mid- to late-proliferative phase and was almost nondetectable in the secretory phase, early proliferative phase, and hormone-deprived animals (in Fig. 1Go, compare E with A, I, and M). Control sections incubated with sense probe or RNase-treated sections incubated with the antisense probe showed signals similar to background and on the glass slide away from the sections (data not shown). Grain counts of the ISH preparations (Fig. 3Go, A–C) confirmed these observations. NP-1 expression in the stroma (Fig. 3AGo) and vascular endothelium (Fig. 3BGo) showed no statistically significant changes during the menstrual cycle or in hormone-deprived animals. However, in the luminal epithelium, the NP-1 mRNA signal was significantly (P < 0.01) up-regulated during the mid- to late-proliferative phase, suppressed to low or nondetectable levels by P treatment during the mid- to late-secretory phases, and also very low in hormone-deprived animals and the newly formed epithelium during the early-proliferative phase (Fig. 3CGo).



View larger version (141K):
[in this window]
[in a new window]
  		FIG. 1. Cellular localization of NP-1 mRNA expression by ISH in different hormonal conditions of rhesus macaque endometrium. The different hormonal conditions are presented as groups of four images. For each hormonal condition, the upper images (A-B, E-F, I-J, M-N) show the luminal epithelium (LE), and the lower images (C-D, G-H, K-L, O-P) show glands (Gl) and stroma (S) in the same section. For each hormonal condition, the left column shows dark-field images, and the right column shows the corresponding bright-field images (original magnification, x120). Note that NP-1 mRNA is strongly expressed in the luminal epithelium during the late-proliferative phase (E-F) and is nondetectable during other stages of the cycle (A-B, I-J, M-N).

 


View larger version (58K):
[in this window]
[in a new window]
  		FIG. 2. NP-1 and NP-2 mRNA expression in the blood vessels (arteries and veins) of rhesus macaque endometrium. The left column represents sections from late-proliferative phase and the right column from late-secretory phase of the cycle. Panel I shows NP-1 mRNA expression in endothelium (arrows) of the spiral arteries (A and B) and veins (C and D), and panel II shows NP-2 mRNA expression in the spiral arteries (E and F) and veins (G and H) in the late-proliferative and late-secretory phases. NP-1 is highly expressed in the endothelium of both arteries and veins (A–D), whereas NP-2 expression is evident only in the veins during the late-secretory phase (H). Panel III (bar diagram) shows grain counts in the endothelium of veins in the late-proliferative and late-secretory phases. There was a significant (*, P < 0.01) up-regulation of the NP-2 mRNA signal in the late-secretory phase.

 


View larger version (31K):
[in this window]
[in a new window]
  		FIG. 3. Analysis of NP-1 mRNA expression by silver grain counts (ISH) in different cell types (A, stroma; B, endothelium; C, luminal epithelium) and percent of Ki-67-positive, proliferating luminal epithelial cells (D). Different bars (mean ± SE) represent different hormonal conditions of endometrium; EarlyPro, Early proliferative; MidPro, midproliferative; LatePro, late-proliferative; MidSecr, midsecretory; LateSecr, late-secretory; and HD10–14, 10–14 d of HD. The pattern of NP-1 mRNA expression (C) in the luminal epithelium parallels that of Ki-67 expression (D). Bars marked with asterisks are significantly (P < 0.01) different from others, and bars marked with letter a are significantly (P < 0.05) different from letter b.

 
Correlation of NP-1 mRNA and Ki-67 expression

Combination immunohistochemistry with Ki-67 and vWF antibodies clearly marked proliferating blood vessels and distinguished them from proliferating stromal and luminal epithelial cells (Fig. 4Go). Cell counts on such preparations showed a significant increase in luminal epithelial cell proliferation in the mid- to late-proliferative stage (Fig. 3DGo). This increase in proliferation was E2 dependent because similar changes did not occur in the absence of E2 in hormone-deprived animals (Fig. 3DGo, HD 10–14). After P treatment, the percentage of proliferating luminal epithelial cells was dramatically reduced during the midsecretory phase (P < 0.01) and was nondetectable during the late-secretory phase (Figs. 3DGo and 4CGo). In the luminal epithelium, the pattern of NP-1 mRNA expression paralleled the pattern of proliferation throughout the cycle. For example, in the luminal epithelium, the Ki-67 labeling index and the NP-1 mRNA grain counts were highly correlated (R2 = 0.895, P < 0.001). However, there were no significant correlations between Ki-67 and NP-1 expression in either the vascular endothelium (R2 = 0.010, P < 0.692) or stroma (R2 = 0.168, P < 0.090) (data not shown).



View larger version (154K):
[in this window]
[in a new window]
  		FIG. 4. Representative sections showing detection of proliferating cells in the endometrium by immunocytochemical localization of Ki-67. vWF coimmunostaining was used to detect endothelial cells (arrows). Early proliferative (d 5) (A), late-proliferative (B), late-secretory (C), and 14 d HD (D). LE, Luminal epithelium; Gl, gland; and S, stroma. Most of the luminal epithelial cells in the late-proliferative endometrium are immunopositive for Ki-67. Original magnification, x120.

 
NP-2 mRNA cellular localization

During the menstrual cycle, NP-2 mRNA expression was confined to the endothelium of small and large veins (Fig. 2HGo) in the endometrium. No specific signal was evident in the endothelium of spiral arteries (Fig. 2Go, E and F), stroma, glands, or luminal epithelium (data not shown). This venous signal was very low or nondetectable during the proliferative phase (Fig. 2GGo) and hormone-deprived animals (data not shown) and was significantly (P < 0.001) up-regulated by P during the secretory phase (Fig. 2Go, panel III).

The human endometrium

Overall the pattern of expression and cellular localization of both NP-1 and NP-2 in the human endometrium during the menstrual cycle was essentially identical with that seen in the rhesus macaque endometrium. In the luminal epithelium, NP-1 expression was elevated during the proliferative phase and undetectable during the secretory phase (compare Fig. 5AGo vs. 5C). In the stroma and vessels, NP-1 mRNA was abundantly and constantly expressed without change during the cycle (Fig. 5Go, E–L), and in the glands, NP-1 mRNA was nondetectable at all times (Fig. 5Go, E–H). As in the macaque, NP-2 expression was evident only in large and small veins of three samples during the secretory phase and was undetectable in any samples from the proliferative phase (Fig. 5Go, M–P).



View larger version (129K):
[in this window]
[in a new window]
  		FIG. 5. ISH showing cellular localization of NP-1 (A–L) and NP-2 (M–P) mRNA expression in the human endometrium. The first and third columns show dark-field images from proliferative and secretory phase endometrium, respectively, and the second and fourth columns show respective bright-field images. The upper three panels show NP-1 mRNA expression in the luminal epithelium (LE) (A–D), glands (Gl), and stroma (S) (E–H), and endothelium (arrows) (I–L); and the fourth panel shows NP-2 mRNA expression in the endothelium of veins (arrows) (M–P). Throughout the cycle, NP-1 mRNA was highly expressed in the stroma (E–H) and blood vessels (I–L) but not in the glands (E–H). In the luminal epithelium, NP-1 was intensely expressed during the proliferative phase (A and B) but was nondetectable during the secretory phase (C and D). In A and C, a white line was drawn to demarcate LE from the underlying stroma. NP-2 expression was evident only in the veins during the secretory phase (O and P).

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Cell-specific localization of NP-1 and -2 mRNA

This is the first report on the cellular localization and hormonal regulation of NP-1 and NP-2 mRNA in the primate endometrium. The expression of these NPs is cell type specific. For example, NP-1 mRNA is expressed by the luminal, but not the glandular, epithelium. It is present in the endothelium of both arteries and veins and is expressed by endometrial stromal cells. NP-2 mRNA was expressed only by the endothelium of veins. In agreement with our findings, Gluzman-Poltorak et al. (18) noted that both NP-1 and NP-2 were expressed in human endothelial cells derived from the umbilical vein; and NP-2 is expressed preferentially in veins in chick embryos (33). Furthermore, in the mouse uterus, VEGFR-2 mRNA is exclusively expressed in endothelial cells, whereas NP-1 mRNA is expressed in both endothelial and stromal cells (26). However, there appear to be species differences because Pavelock et al. (27), who studied the rat uterus, reported that NP-1 protein (by ICC) was expressed in glands and vessels, and NP-2 was seen only in glandular epithelium, not vessels. It is not clear whether NP-1 is expressed in the mouse and rat uterine luminal epithelium because the latter two studies did not comment on luminal epithelial expression. Although we tried several commercially available NP-1 and -2 antibodies to examine protein localization by ICC, most of these antibodies are indicated for use in Western blots, and they were not satisfactory as ICC reagents in either human or rhesus monkey endometrium. We plan future studies to evaluate NP-1 and -2 protein expression in different endometrial cell types by laser capture microdissection and Western blotting.

NP-1 mRNA expression in the luminal epithelium is estrogen dependent

NP-1 mRNA expression in luminal epithelium was high during the mid- to late-proliferative phase, down-regulated in the secretory phase, and absent during hormone deprivation. Because only E2 was present during the induced proliferative phase and because P is known to block many estrogen-dependent processes, these data indicate that the increased expression of NP-1 mRNA was estrogen driven. Also, the low expression of NP-1 mRNA in the luminal epithelium of the hormone-deprived group is consistent with estrogen dependence because these animals lacked both E2 and P. VEGF, which is also estrogen dependent in the primate endometrium (31, 34), can mediate estrogen-dependent proliferation in the luminal epithelium in mice (15) and can induce epithelial cell proliferation in human fetal lung tissue (35). However, classical VEGFRs (VEGFR-1 and VEGFR-2) are lacking in the luminal epithelium of the primate endometrium (31). Because our data reveal that NP-1 mRNA expression is highly correlated with the proliferation marker Ki-67 in the luminal epithelium, we hypothesize that NP-1 mediates the proliferative effects of VEGF on these cells in the primate endometrium. Studies with antagonists of VEGF and NP-1 in the primate endometrium are needed to test this hypothesis.

However, during the postmenstrual repair (early proliferative) phase, NP-1 mRNA signal was very low in the newly formed luminal epithelium in the presence of E2, indicating that E2 has no regulatory role on NP-1 expression during this period. We previously reported that expression of VEGF, VEGFR-1, and VEGFR-2 is also independent of E2 action during the postmenstrual repair phase (31). In fact, postmenstrual healing and reepitheliazation of primate endometrium can occur normally after P withdrawal in the absence of E2 (2).

Surprisingly, the NP-1 gene in endometrial stroma and blood vessels showed no responsiveness to changes in hormonal state. Rather, expression in these cells was similar throughout the cycle and during hormone deprivation. The specific functions of NP-1 in these cells are currently not clear. However, in the vessels, NP-1 may function as an enhancer of tyrosine-kinase receptor (VEGFR-1 and -2) signaling because these receptors are also expressed in the vascular endothelium throughout the cycle (31), and NP-1 is known to form complexes with both VEGFR-1 and -2 and stimulate VEGF165 activity (22). In the stroma, NP-1 may also play a similar role to enhance VEGF activity when other tyrosine kinase receptors are expressed in the stromal cells. For example, in an earlier study, we have shown transient expression of VEGFR-2 in the stromal cells during the premenstrual/menstrual phase and a potential role of VEGF in induction of matrix metalloproteinases in these cells (11). Nevertheless, the difference in NP-1 regulation implies that cell-specific regulatory factors, rather than gene promoter differences, are responsible for these differences in hormonal responsiveness. Consequently, studies aimed at discovering which cell-specific factors regulate NP-1 gene expression in the different cell types of the primate endometrium should be of high priority.

We recently observed expression of semaphorin E, another ligand for NP-1, in the human endometrium (32). Its expression was down-regulated in the secretory phase during the window of implantation. But semaphorin E level was elevated in the endometrium of patients with endometriosis during the window of implantation (36). Thus, semaphorin actions may be mediated through NP-1 in the primate endometrium. Additional studies are underway in our laboratory to examine cellular localization and hormonal regulation of different members of this family of ligands and possible interactions with NPs in regulating endometrial functions.

NP-2 mRNA expression in the venous endothelium is P dependent

NP-2 mRNA provides a further example of cellular and regulatory specificity because it is expressed only in the venous endothelium and is up-regulated by P, not E2. Pavelock et al. (27) reported no change in NP-2 expression during the estrous cycle in the rat uterus and suppression of NP-2 by E2. However, in our study, NP-2 was not up-regulated in hormone-deprived macaques.

Of the various receptors expressed in vascular endothelium, including VEGFR-1, VEGFR-2, and NP-1, only NP-2 is up-regulated in the venous endothelium during the secretory phase. Because VEGF acts in the primate endometrium during the secretory phase to enhance permeability, venous NP-2 could mediate this effect. VEGF is a potent permeability factor (5, 6), and the edema it induces immediately subjacent to the luminal epithelium of the primate endometrium is essential for proper implantation (1, 3, 4, 5). Also, NP-1 and -2 can form heteromultimer complexes (37), and NP-1/NP-2 double-knockout mice show severe abnormal vascular phenotype, compared with single knockouts (25). Thus, expression of NP-2 in addition to NP-1 in the secretory phase venous endothelium may further potentiate VEGF action in this endothelium.

In summary, our ISH of NP-1 and NP-2 revealed that these VEGFRs are expressed in a cell-specific and hormonally responsive manner in the endometrium of both cycling women and nonhuman primates. NP-1 is expressed by several cell types, but hormonal regulation of this receptor occurs only in the luminal epithelium. In these cells, NP-1 expression is highly correlated with Ki-67 expression, an indication that NP-1 could mediate VEGF-dependent luminal epithelial proliferation. NP-2 mRNA exists at significant levels only in veins and only during the secretory phase of the menstrual cycle, in which it could mediate the inductive effects of VEGF on physiological edema. Because there is no shift in expression of the major VEGF isoform (VEGF165) during the menstrual cycle, it appears that hormonally induced, cell-specific expression of these isoform-specific receptors may be an important factor in mediating VEGF functions in the primate endometrium. Additional research is essential to discover the cell-specific factors that regulate NP expression and function in the primate endometrium.


   Acknowledgments
 
We thank Kunie Mah (Oregon National Primate Research Center, Beaverton, OR) and Kim Chi Vo (Stanford University, Stanford, CA) for technical assistance.


   Footnotes
 
This work was supported by the Andrew Mellon Foundation (to N.R.N.), National Institutes of Health (NIH) Building Interdisciplinary Research Careers in Women’s Health Program (to N.R.N.), NIH HD 031398 (U54 SCCPR) Endometrial Tissue and DNA Bank at Stanford (to L.C.G.), NIH HD19182 (to R.M.B.), and the German Research Foundation (GE 1173/1-2, postdoctoral fellowship to A.G.).

Present address for A.G.: Department of Reproductive Endocrinology and Infertility, University of Heidelberg, Heidelberg, Germany.

First Published Online December 21, 2004

Abbreviations: E, Embryonic day; E2, estradiol; HD, hormone deprived; ICC, immunocytochemistry; ISH, in situ hybridization; NP, neuropilin; P, progesterone; PVP, polyvinylpyrollidone; SSC, standard saline citrate; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; vWF, von Willebrand factor.

Received September 7, 2004.

Accepted December 12, 2004.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Lessey BA 2002 Uterine factors in implantation. In: Glasser SR, Aplin JD, Giudice LC, Tabibzadeh S, eds. The endometrium. 1st ed. New York: Taylor and Francis Group; 208–228
  2. Brenner RM, Rudolph L, Matrisian L, Slayden OD 1996 Non-human primate models; artificial menstrual cycles, endometrial matrix metalloproteinases and s.c. endometrial grafts. Hum Reprod 11(Suppl 2):150–164
  3. Paria BC, Reese J, Das SK, Dey SK 2002 Deciphering the cross-talk of implantation: advances and challenges. Science 296:2185–2188[Abstract/Free Full Text]
  4. Giudice LC 1999 Potential biochemical markers of uterine receptivity. Hum Reprod 14(Suppl 2):3–16
  5. Smith SK 1998 Angiogenesis, vascular endothelial growth factor and the endometrium. Hum Reprod Update 4:509–519[Abstract/Free Full Text]
  6. Ferrara N, Davis-Smyth T 1997 The biology of vascular endothelial growth factor. Endocr Rev 18:4–25[Abstract/Free Full Text]
  7. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z 1999 Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9–22[Abstract/Free Full Text]
  8. Torry DS, Holt VJ, Keenan JA, Harris G, Caudle MR, Torry RJ 1996 Vascular endothelial growth factor expression in cycling human endometrium. Fertil Steril 66:72–80[Medline]
  9. Huang JC, Liu DY, Dawood MY 1998 The expression of vascular endothelial growth factor isoforms in cultured human endometrial stromal cells and its regulation by 17ß-oestradiol. Mol Hum Reprod 4:603–607[Abstract/Free Full Text]
  10. Ancelin M, Buteau-Lozano H, Meduri G, Osborne-Pellegrin M, Sordello S, Plouet J, Perrot-Applanat M 2002 A dynamic shift of VEGF isoforms with a transient and selective progesterone-induced expression of VEGF189 regulates angiogenesis and vascular permeability in human uterus. Proc Natl Acad Sci USA 99:6023–6028[Abstract/Free Full Text]
  11. Nayak NR, Critchley HO, Slayden OD, Menrad A, Chwalisz K, Baird DT, Brenner RM 2000 Progesterone withdrawal up-regulates vascular endothelial growth factor receptor type 2 in the superficial zone stroma of the human and macaque endometrium: potential relevance to menstruation. J Clin Endocrinol Metab 85:3442–3452[Abstract/Free Full Text]
  12. Wang DS, Miura M, Demura H, Sato K 1997 Anabolic effects of 1,25-dihydroxyvitamin D3 on osteoblasts are enhanced by vascular endothelial growth factor produced by osteoblasts and by growth factors produced by endothelial cells. Endocrinology 138:2953–2962[Abstract/Free Full Text]
  13. Midy V, Plouet J 1994 Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. Biochem Biophys Res Commun 199:380–386[CrossRef][Medline]
  14. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D 1996 Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87:3336–3343[Abstract/Free Full Text]
  15. Hastings JM, Licence DR, Burton GJ, Charnock-Jones DS, Smith SK 2003 Soluble vascular endothelial growth factor receptor 1 inhibits edema and epithelial proliferation induced by 17ß-estradiol in the mouse uterus. Endocrinology 144:326–334[Abstract/Free Full Text]
  16. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M 1998 Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735–745[CrossRef][Medline]
  17. Nakamura F, Tanaka M, Takahashi T, Kalb RG, Strittmatter SM 1998 Neuropilin-1 extracellular domains mediate semaphorin D/III-induced growth cone collapse. Neuron 21:1093–1100[CrossRef][Medline]
  18. Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G 2000 Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J Biol Chem 275:18040–18045[Abstract/Free Full Text]
  19. Migdal M, Huppertz B, Tessler S, Comforti A, Shibuya M, Reich R, Baumann H, Neufeld G 1998 Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 273:22272–22278[Abstract/Free Full Text]
  20. Makinen T, Olofsson B, Karpanen T, Hellman U, Soker S, Klagsbrun M, Eriksson U, Alitalo K 1999 Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem 274:21217–21222[Abstract/Free Full Text]
  21. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M 2002 VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 85:357–368[CrossRef][Medline]
  22. Neufeld G, Kessler O, Herzog Y 2002 The interaction of neuropilin-1 and neuropilin-2 with tyrosine-kinase receptors for VEGF. Adv Exp Med Biol 515:81–90[Medline]
  23. Kitsukawa T, Shimono A, Kawakami A, Kondoh H, Fujisawa H 1995 Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 121:4309–4318[Abstract]
  24. Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M 2000 Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 14:2532–2539[Abstract/Free Full Text]
  25. Takashima S, Kitakaze M, Asakura M, Asanuma H, Sanada S, Tashiro F, Niwa H, Miyazaki Ji J, Hirota S, Kitamura Y, Kitsukawa T, Fujisawa H, Klagsbrun M, Hori M 2002 Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci USA 99:3657–3662[Abstract/Free Full Text]
  26. Halder JB, Zhao X, Soker S, Paria BC, Klagsbrun M, Das SK, Dey SK 2000 Differential expression of VEGF isoforms and VEGF(164)-specific receptor neuropilin-1 in the mouse uterus suggests a role for VEGF(164) in vascular permeability and angiogenesis during implantation. Genesis 26:213–224[CrossRef][Medline]
  27. Pavelock K, Braas K, Ouafik L, Osol G, May V 2001 Differential expression and regulation of the vascular endothelial growth factor receptors neuropilin-1 and neuropilin-2 in rat uterus. Endocrinology 142:613–622[Abstract/Free Full Text]
  28. Michael RP, Zumpe D 1970 Rhythmic changes in the copulatory frequency of rhesus monkeys (Macaca mulatta) in relation to the menstrual cycle and a comparison with the human cycle. J Reprod Fertil 21:199–201
  29. Rudolph-Owen LA, Slayden OD, Matrisian LM, Brenner RM 1998 Matrix metalloproteinase expression in Macaca mulatta endometrium: evidence for zone-specific regulatory tissue gradients. Biol Reprod 59:1349–1359[Abstract/Free Full Text]
  30. West NB, Hess DL, Brenner RM 1986 Differential suppression of progesterone receptors by progesterone in the reproductive tract of female macaques. J Steroid Biochem 25:497–503[CrossRef][Medline]
  31. Nayak NR, Brenner RM 2002 Vascular proliferation and vascular endothelial growth factor expression in the rhesus macaque endometrium. J Clin Endocrinol Metab 87:1845–1855[Abstract/Free Full Text]
  32. Kao LC, Tulac S, Lobo S, Imani B, Yang JP, Germeyer A, Osteen K, Taylor RN, Lessey BA, Giudice LC 2002 Global gene profiling in human endometrium during the window of implantation. Endocrinology 143:2119–2138[Abstract/Free Full Text]
  33. Herzog Y, Kalcheim C, Kahane N, Reshef R, Neufeld G 2001 Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech Dev 109:115–119[CrossRef][Medline]
  34. Albrecht ED, Pepe GJ 2003 Steroid hormone regulation of angiogenesis in the primate endometrium. Front Biosci 8:d416–429
  35. Brown KR, England KM, Goss KL, Snyder JM, Acarregui MJ 2001 VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol 281:L1001–L1010
  36. Kao LC, Germeyer A, Tulac S, Lobo S, Yang JP, Taylor RN, Osteen K, Lessey BA, Giudice LC 2003 Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology 144:2870–2881[Abstract/Free Full Text]
  37. Giger RJ, Urquhart ER, Gillespie SK, Levengood DV, Ginty DD, Kolodkin AL 1998 Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of receptor function and specificity. Neuron 21:1079–1092[CrossRef][Medline]



This article has been cited by other articles:


Home page
 FASEB J.Home page
X. Fan, S. Krieg, C. J. Kuo, S. J. Wiegand, M. Rabinovitch, M. L. Druzin, R. M. Brenner, L. C. Giudice, and N. R. Nayak
VEGF blockade inhibits angiogenesis and reepithelialization of endometrium
FASEB J, October 1, 2008; 22(10): 3571 - 3580.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
T. Strowitzki, A. Germeyer, R. Popovici, and M. von Wolff
The human endometrium as a fertility-determining factor
Hum. Reprod. Update, September 1, 2006; 12(5): 617 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
C. Punyadeera, V.L. Thijssen, S. Tchaikovski, R. Kamps, B. Delvoux, G.A.J. Dunselman, A.F.P.M. de Goeij, A.W. Griffioen, and P.G. Groothuis
Expression and regulation of vascular endothelial growth factor ligands and receptors during menstruation and post-menstrual repair of human endometrium
Mol. Hum. Reprod., June 1, 2006; 12(6): 367 - 375.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
N. R. Nayak, C. J. Kuo, T. A. Desai, S. J. Wiegand, B. L. Lasley, L. C. Giudice, and R. M. Brenner
Expression, localization and hormonal control of angiopoietin-1 in the rhesus macaque endometrium: potential role in spiral artery growth
Mol. Hum. Reprod., November 1, 2005; 11(11): 791 - 799.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Germeyer, A.
Right arrow Articles by Nayak, N. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Germeyer, A.
Right arrow Articles by Nayak, N. R.
Related Collections
Right arrow Female Endocrinology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals